Order Article Reprints

Spiliopoulou V, Ntanasis-Stathopoulos I, Malandrakis P, Gavriatopoulou M, Theodorakakou F, Fotiou D, Migkou M, Roussou M, Eleutherakis-Papaiakovou E, Kastritis E, et al. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study. Viruses. 2023; 15(3):704. https://doi.org/10.3390/v15030704

Spiliopoulou, Vassiliki, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, and et al. 2023. "Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study" Viruses 15, no. 3: 704. https://doi.org/10.3390/v15030704

Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Gavriatopoulou, M., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Eleutherakis-Papaiakovou, E., Kastritis, E., Dimopoulos, M. A., & Terpos, E. (2023). Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study. Viruses, 15(3), 704. https://doi.org/10.3390/v15030704